Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Methylprednisolone With Clot Removal for Large Stroke

Tests methylprednisolone with clot removal in adults with large ischemic strokes.

Key facts

Who runs it
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Where
Guangzhou, ChinaSee the site
Trial code
Registry title
Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke
Status
Not yet recruiting
Phase
Phase 3
People taking part
1,614 people, planned
Started
Apr 2025
Expected to end
Apr 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Methyprednisolone sodium succinate
  • Placebo
Record updated
11 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a sudden stroke caused by a blocked large artery in the front of the brain and a large area of damaged brain, who plan to have clot removal (thrombectomy).

Age
18 years or older
Sex
All sexes can join
Disease stage
Sudden (acute) ischemic stroke with NIHSS 6 or higher. Blocked intracranial internal carotid artery or M1/M2 part of the middle cerebral artery, confirmed by imaging. Large damaged area: ASPECTS 5 or lower, or infarct core volume 70mL or more. Within 24 hours of last known well.
Earlier treatment
Must plan to have endovascular thrombectomy (EVT). Before the stroke, mRS score of 0-2.

Main reasons for not taking part

  • Bleeding inside the skull on CT or MRI
  • Allergy to glucocorticoids, placebo components or contrast agent
  • Severe infection or other reason not to use glucocorticoids
  • Bleeding or clotting problems, or blood thinner use as described in the record
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • 1. Age ≥18 years
  • 2. Clinically diagnosed with acute ischemic stroke and NIHSS ≥6
  • 3. CT angiography (CTA), MR angiography (MRA) or digital subtraction angiography (DSA) confirmed occlusion of intracranial internal carotid artery (ICA) or M1/M2 segments of middle cerebral artery (MCA) and plan to undergo EVT
  • 4. ASPECTS ≤5 (based on NCCT) or infarct core volume ≥70mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI)
  • 5. Time from symptom onset to randomization within 24 hours (from last known well)
  • 6. Pre-stroke mRS score 0-2
  • 7. Written informed consent signed by patients or their family members

Who cannot take part

  • 1. Intracranial hemorrhage confirmed by CT or MRI
  • 2. Allergic to glucocorticoids or placebo components
  • 3. Allergic to contrast agent
  • 4. Presence of severe infectious disease unsuitable for glucocorticoid therapy or any other contraindication to glucocorticoid use
  • 8. History of gastrointestinal or urinary tract bleeding within the last month
  • 12. Uncontrolled hypertension with persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, refractory to medical management
  • 13. Life expectancy less than 6 months due to malignancy or severe cardiopulmonary disease
  • 14. Other conditions deemed unsuitable for the study by the investigator, such as inability to comprehend or comply with study procedures or follow-up due to mental illness, cognitive or emotional disorder
  • 5. Known genetic or acquired coagulopathy, coagulation factor deficiency, use of warfarin with an international normalized ratio (INR) >1.7, or use of novel oral anticoagulants within 48 hours of symptom onset
  • 6. Platelet count <90×10\^9/L
  • 7. Random blood glucose <2.8 mmol/L or >22.2 mmol/L
  • 11. Renal dysfunction (glomerular filtration rate <30 ml/min or serum creatinine >220 μmol/L [2.5 mg/dl])
  • 9. Current participation in another interventional clinical study
  • 10. Pregnant or lactating women

Where in China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaContact: Xinguang YangNo longer taking part

About the trial

What the trial wants to find out

It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vascular occlusion (LVO) patients with a large infarct core. In this study, the investigators assume that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone for patients who have evidence of a large infarct volume. The objective of the study was to establish the efficacy and safety of methylprednisolone with EVT in patients presenting with symptoms of acute ischemic stroke from LVO in the anterior circulation and having a large infarct volume.

The 2 groups in the trial

  • Methylprednisolone groupTreatment being tested

    Methylprednisolone sodium succinate

    Treatment: Methyprednisolone sodium succinate

  • Placebo groupPlacebo, for comparison

    Methylprednisolone sodium succinate simulant

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke (MATCH): A Randomized Controlled Trial
Plain-language title
Methylprednisolone With Clot Removal for Large StrokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 March 2025